AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: 2.5 mg ONGLYZA® (saxagliptin) tabletDrug: 5 mg Forxiga® (dapagliflozin) tabletDrug: 500 mg Glucophage XR®
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 126
- Registration Number
- NCT03138356
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Other
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT03137264
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT03136991
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT03133234
- Locations
- 🇨🇳
Kiang Wu Hospital, Macau, China
Realize the Current Situation of COPD Patients in China
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease COPD
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5020
- Registration Number
- NCT03131362
- Locations
- 🇨🇳
Research Site, Beijing, China
ZS Ph2/3 Dose-response Study in Japan
Phase 2
Completed
- Conditions
- Hyperkalemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (ZS) 5gDrug: Sodium Zirconium Cyclosilicate (ZS) 10gDrug: Placebo
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 103
- Registration Number
- NCT03127644
- Locations
- 🇯🇵
Research Site, Yotsukaido-shi, Japan
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
Phase 1
Completed
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT03126695
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
Phase 2
Completed
- Conditions
- HyperuricemiaAlbuminuriaType 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT03118739
- Locations
- 🇺🇸
Research Site, Webster, Texas, United States
Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population
Completed
- Conditions
- Gastrointestinal Disease
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90895
- Registration Number
- NCT03118778
- Locations
- 🇨🇳
Research Site, Beijing, China
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
Phase 3
Completed
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 220
- Registration Number
- NCT03106987
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath